Online Only Articles

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

1Medical Clinic and Policlinic I, University Hospital Dresden, Germany
1Medical Clinic and Policlinic I, University Hospital Dresden, Germany
2Department of Hematology/Oncology, Hannover Medical School, Germany
3Department of Bone Marrow Transplantation, University Hospital Essen, Germany
1Medical Clinic and Policlinic I, University Hospital Dresden, Germany
4Department of Internal Medicine II, Wuerzburg University Medical Center, Germany
5Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University of Düsseldorf, Germany
6Department of Medicine 1, Hematology/Oncology, University Hospital Freiburg, Germany
5Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University of Düsseldorf, Germany
1Medical Clinic and Policlinic I, University Hospital Dresden, Germany
7Department of Internal Medicine III, University of Ulm, Germany
3Department of Bone Marrow Transplantation, University Hospital Essen, Germany
1Medical Clinic and Policlinic I, University Hospital Dresden, Germany
1Medical Clinic and Policlinic I, University Hospital Dresden, Germany
1Medical Clinic and Policlinic I, University Hospital Dresden, Germany
Vol. 97 No. 9 (2012): September, 2012 https://doi.org/10.3324/haematol.2012.067629